BioSpace News Archive

Meridian Bioscience, Inc. (NASDAQ: VIVO), announced today the continued expansion of its isothermal amplification product line with the launch of two new innovative master mixes, Lyo-Ready™ Direct DNA LAMP Saliva Mix and Lyo-Ready™ Direct RNA/DNA LAMP Saliva Mix.

The Sabin Vaccine Institute was awarded up to $6.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) for a clinical trial to evaluate the immunogenicity and safety of lower, fractional doses of registered COVID-19 vaccines used as a booster dose.

ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference.

Casma Therapeutics, Inc. announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the UBS 2022 Global Healthcare Conference on Tuesday, May 24, 2022 at 11:30 a.m. ET in New York, NY.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022.

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced results from a preclinical study of RKER-012 on pulmonary arterial pressure and right ventricle hypertrophy in an established rodent model of pulmonary arterial hypertension (“PAH”) at the American Thoracic Society (“ATS”) International Conference held May 13 through 18, 2022.

XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 10:00 AM ET.

Histogen Inc. announced that Steven J. Mento, Ph.D., Histogen’s Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.

Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, will participate in the following upcoming investor conferences.

Talaris Therapeutics, Inc. announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.